MedPath
HSA Approval

GAVISCON LIQUID

SIN09494P

GAVISCON LIQUID

GAVISCON LIQUID

September 13, 1997

RECKITT BENCKISER (SINGAPORE) PTE LTD

RECKITT BENCKISER (SINGAPORE) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantRECKITT BENCKISER (SINGAPORE) PTE LTD
Licence HolderRECKITT BENCKISER (SINGAPORE) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
General Sale List
HSA Singapore Classification

Formulation Information

SUSPENSION

ORAL

Medical Information

A02BX13

alginic acid

Manufacturer Information

RECKITT BENCKISER (SINGAPORE) PTE LTD

RECKITT BENCKISER HEALTHCARE (UK) LTD

Active Ingredients

CALCIUM CARBONATE

160 mg/10 ml

Calcium carbonate

SODIUM BICARBONATE

267 mg/10 ml

Sodium bicarbonate

SODIUM ALGINATE

500 mg/10 ml

Alginic acid

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

GAVISCON LIQUID - HSA Approval | MedPath